Pfizer Inc. $PFE Stock: Sumitomo Mitsui Trust Group Inc. Cuts Stake

Sumitomo Mitsui Trust Group Inc. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 13,596,756 shares of the biopharmaceutical company’s stock after selling 179,173 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Pfizer were worth $387,779,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in PFE. Russell Investments Group Ltd. raised its position in Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after acquiring an additional 745,213 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after acquiring an additional 232,528 shares during the last quarter. Leuthold Group LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $4,887,000. Park National Corp OH grew its position in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after acquiring an additional 186,053 shares during the period. Finally, 111 Capital purchased a new stake in shares of Pfizer in the 2nd quarter worth $3,706,000. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. HSBC boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Scotiabank upped their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. JPMorgan Chase & Co. lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Finally, Cantor Fitzgerald boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Five research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.65.

Pfizer Stock Up 1.8%

PFE opened at $30.48 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.67. The firm’s fifty day moving average is $28.55 and its 200 day moving average is $26.79. The stock has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.32.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.6%. Pfizer’s dividend payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.